Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care

LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform care within five years. Drugs to Watch has consistently identified therapies that redefine patient care, with over 110 featured to date, making it a central reference for tracking innovation in the pharmaceutical sector.